Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy .
Analyst Price Forecast Suggests 42.04% Upside
As of August 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is 21.76. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 42.04% from its latest reported closing price of 15.32.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 8.87%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 363 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 11 owner(s) or 3.12% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. Total shares owned by institutions increased in the last three months by 12.15% to 61,582K shares. 
The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
What are Other Shareholders Doing?
Redmile Group holds 5,582K shares representing 7.11% ownership of the company. In it's prior filing, the firm reported owning 3,593K shares, representing an increase of 35.63%. The firm increased its portfolio allocation in DCPH by 55.33% over the last quarter.
Deerfield Management Company, L.p. holds 5,219K shares representing 6.65% ownership of the company. In it's prior filing, the firm reported owning 2,349K shares, representing an increase of 54.98%. The firm increased its portfolio allocation in DCPH by 125.52% over the last quarter.
Armistice Capital holds 4,100K shares representing 5.22% ownership of the company. In it's prior filing, the firm reported owning 5,172K shares, representing a decrease of 26.15%. The firm decreased its portfolio allocation in DCPH by 38.32% over the last quarter.
Braidwell holds 3,241K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 3,272K shares, representing a decrease of 0.93%. The firm decreased its portfolio allocation in DCPH by 8.08% over the last quarter.
Goldman Sachs Group holds 3,058K shares representing 3.89% ownership of the company. In it's prior filing, the firm reported owning 2,200K shares, representing an increase of 28.04%. The firm increased its portfolio allocation in DCPH by 24.93% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Additional reading:
- Press Release issued by Deciphera Pharmaceuticals, Inc. on August 9, 2023
- , dated May 3, 2023, by and between Deciphera Pharmaceuticals, LLC and Jefferies LLC
- Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol,
- Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results – First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in th
- Form of indenture for senior debt securities and the related form of senior debt security.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
